Dako, Genentech Partner on Regulatory Submission of CDx for Second Breast Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Dako has signed an agreement with Genentech to partner on the regulatory submission of companion diagnostic tests for a breast cancer drug.

Under the agreement announced today, the companies will collaborate on the US Food and Drug Administration submission of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for Genentech's trastuzumab emtansine, an investigational drug candidate for patients with advanced HER2-positive breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.